Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines Full Text available with Trip Pro

Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines Redirecting

2021 Integrative medicine research

2. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer T echnology appraisal guidance Published: 10 March 2021 www.nice.org.uk/guidance/ta683 © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non- squamous non-small-cell lung cancer (TA683) © NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2021 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer CUAJ – CUA Best Practice Report Shayegan et al BPR: PSMA PET in prostate cancer 1 © 2021 Canadian Urological Association Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic (...) resonance (MR) in prostate cancer Bobby Shayegan *1 ; Katherine Zukotynski *2 ; François Bénard 3,4 ; Cynthia Ménard 5 ; Golmehr Sistani 6 ; Glenn Bauman 7 ; Patrick Veit-Haibach 8 ; Ur Metser 9 1 Department of Urology, McMaster University, Hamilton, ON, Canada; 2 Departments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada; 3 PET Functional Imaging, BC Cancer, Vancouver, BC, Canada; 4 Department of Radiology, University of British Columbia, Vancouver, BC, Canada; 5 Department

2021 Canadian Urological Association

4. Management of advanced kidney cancer

Management of advanced kidney cancer CUAJ • April 2021• Volume 15, Issue 4 © 2021 Canadian Urological Association KCRNC CONSENSUS STATEMENT 84 Cite as: Canil C, Kapoor A, Basappa NS, et al. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Can Urol Assoc J 2021;15(4):84- 97. http://dx.doi.org/10.5489/cuaj.7245 The following is a consensus report from the Kidney Cancer Research Network of Canada (KCRNC), with an update from the 11th (...) Canadian Kidney Cancer Forum, held virtually on October 16, 2020, and subsequent discussions and updates after the ASCO Genitourinary Cancers Symposium, held in February 2021. Introduction For more than a decade, targeted systemic therapies have been the standard of care for metastatic renal cell carcinoma (mRCC) and their use has been refined over time as clinical experience has evolved. 1-6 The 2019 consensus statement by the Kidney Cancer Research Network of Canada (KCRNC) introduced the role

2021 Canadian Urological Association

5. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Andrew G. Robinson,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie R. Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson, MD (...) , MACP 13 ; Natasha B. Leighl,MD 14 ; Pamela R. Mof?tt 15 ; Tanyanika Phillips,MD 16 ; Gregory J. Riely, MD, PhD 17 ; Rafael Rosell,MD 18 ; Joan H. Schiller,MD 19 ; Bryan J. Schneider,MD 20 ; Navneet Singh, MD, DM 21 ; David R. Spigel,MD 22 ; Joan Tashbar 23 ;and Gregory Masters,MD 24 abstract PURPOSEToprovideevidence-basedrecommendationsupdatingthe2017ASCOguidelineonsystemictherapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic

2021 Cancer Care Ontario

6. Management of Dyspnea in Advanced Cancer

Management of Dyspnea in Advanced Cancer Management of Dyspnea in Advanced Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.03465 Journal of Clinical Oncology - published online before print February 22, 2021 PMID: Management of Dyspnea in Advanced Cancer: ASCO Guideline , MD 1 x David Hui ; , ScD 2 x Kari Bohlke ; , MD 3 x (...) Ting Bao ; , MD, MS 4 x Toby C. Campbell ; , MSN, ACHPN, ACNS-BC 5 x Patrick J. Coyne ; , BMed, MPH, PhD 6 x David C. Currow ; , MD 7 x Arjun Gupta ; , MD 8 x Aliza L. Leiser ; , MD 9 x Masanori Mori ; , MD 10 x Stefano Nava ; , PhD, ARNP 11 x Lynn F. Reinke ; , MD 12 x Eric J. Roeland ; , MBA 13 x Carole Seigel ; , MD, MSc 14 x Declan Walsh ; and , PhD, RN 15 x Margaret L. Campbell 1 MD Anderson Cancer Center, Houston, TX 2 American Society of Clinical Oncology, Alexandria, VA 3 Memorial Sloan

2021 American Society of Clinical Oncology Guidelines

7. Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations

Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.03570 Journal of Clinical Oncology - published online before print February 16, 2021 PMID: Therapy for Stage IV (...) Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update , MD 1 x Nasser H. Hanna ; , MD 2 x Andrew G. Robinson ; , MSPH 3 x Sarah Temin ; , MD 4 x Sherman Baker Jr ; , MD 5 x Julie R. Brahmer ; , MD, PhD 6 x Peter M. Ellis ; , MD, MBA 7 , 8 x Laurie E. Gaspar ; , MD 9 x Rami Y. Haddad ; , MD 10 x Paul J. Hesketh ; , MD 11 x Dharamvir Jain ; , MD 12 x Ishmael Jaiyesimi ; , MD, MACP 13 x David H. Johnson ; , MD 14 x Natasha B. Leighl ; 15 x Pamela R. Moffitt

2021 American Society of Clinical Oncology Guidelines

8. Effect of Aspirin on Cancer Incidence and Mortality in Older Adults Full Text available with Trip Pro

Effect of Aspirin on Cancer Incidence and Mortality in Older Adults Effect of Aspirin on Cancer Incidence and Mortality in Older Adults - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email Send to Display (...) Format Share Permalink Copy Page navigation J Natl Cancer Inst Actions . 2021 Mar 1;113(3):258-265. doi: 10.1093/jnci/djaa114. Effect of Aspirin on Cancer Incidence and Mortality in Older Adults , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 2 The Walter & Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia; and Department of Medical

2021 EvidenceUpdates

9. Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer: A Systematic Review and Meta-analysis Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving (...) : Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation JAMA Netw Open Actions . 2021 Feb 1;4(2):e2037632. doi: 10.1001/jamanetworkopen.2020.37632. Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer: A Systematic Review and Meta-analysis , , , , , , , , Affiliations Expand Affiliations 1 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 2

2021 EvidenceUpdates

10. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study) Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Eur J Cancer Actions . 2021 Feb;144:61-71. doi: 10.1016/j.ejca.2020.11.007. Epub 2020 Dec 16. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant

2021 EvidenceUpdates

11. Disparities and Barriers to Pediatric Cancer Survivorship Care

Disparities and Barriers to Pediatric Cancer Survivorship Care Disparities and Barriers to Pediatric Cancer Survivorship Care Technical Brief Number 39 R Technical Brief Number 39 Disparities and Barriers to Pediatric Cancer Survivorship Care Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 75Q80120D00009 Prepared by: Southern California Evidence-based Practice Center Los Angeles (...) , CA Investigators: Erin M. Mobley, Ph.D. Diana J. Moke, M.D. Joel Milam, Ph.D. Carol Y. Ochoa, M.P.H. Julia Stal, B.A. Nosa Osazuwa, B.A. Maria Bolshakova, B.S. Jai Kemp, B.A. Jennifer E. Dinalo, Ph.D. Aneesa Motala, B.A. Drizelle Baluyot, B.A. Susanne Hempel, Ph.D. AHRQ Publication No. 21-EHC014 March 2021 ii Key Messages Purpose of Review This Agency for Healthcare Research and Quality (AHRQ) Technical Brief was commissioned by the National Cancer Institute (NCI) to support the development

2021 Effective Health Care Program (AHRQ)

12. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer Guideline 27-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer M.A. Haider, J. Brown, J. Chin, A. Loblaw, N. Perlis, N. Schieda, and the MPMRI in the Diagnosis of Clinically Significant Prostate Cancer Guideline Development Group (...) (Vancouver Style): Haider MA, Brown J, Chin J, Loblaw A, Perlis N, Schieda N. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer. Toronto (ON): Ontario Health (Cancer Care Ontario); 2021 February 11. Program in Evidence-Based Care Guideline No.: 27-2 Version 2, available on the OH (CCO) website. Copyright This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express

2021 Cancer Care Ontario

13. Less radical surgery for early-stage cervical cancer: a systematic review

Less radical surgery for early-stage cervical cancer: a systematic review Less radical surgery for early-stage cervical cancer: a systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save Email (...) options Display options Format Share Permalink Copy Page navigation Review Am J Obstet Gynecol Actions . 2020 Dec 9;S0002-9378(20)31377-6. doi: 10.1016/j.ajog.2020.11.041. Online ahead of print. Less radical surgery for early-stage cervical cancer: a systematic review , , , , , , , , , Affiliations Expand Affiliations 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY; Duke University School

2021 EvidenceUpdates

14. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) -small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain. Electronic address: lpazaresr@seom.org. 2 Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania. 3 Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales

2021 EvidenceUpdates

15. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial Full Text available with Trip Pro

Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Gastroenterology Actions . 2021 Mar;160(4):1085-1096.e5. doi: 10.1053/j.gastro.2020.11.037. Epub 2020 Nov 21. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Section for Colorectal

2021 EvidenceUpdates

16. Bowel cancer screening: guidelines for colonoscopy

Bowel cancer screening: guidelines for colonoscopy Bowel cancer screening: guidelines for colonoscopy - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional cookies You can at any time. Hide this message Show (...) or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check what you need to do Guidance Bowel cancer screening: guidelines for colonoscopy This guidance sets out the process for colonoscopy in the NHS bowel cancer screening programme. From: Published: 1 February 2011 Last updated: 18 February 2021, Applies to: England Documents HTML Details This guidance sets out the process for colonoscopy in the NHS bowel cancer screening programme. It replaces the Quality Assurance Guidelines

2021 Public Health England

17. Trilacicilib (Cosela) - To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer

Trilacicilib (Cosela) - To mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer Drug Approval Package: COSELA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: COSELA Company: G1 Therapeutics, Inc. Application Number: 214200 Approval Date: 2/12/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

18. Tepotinib (Tepmetko) - To treat non-small cell lung cancer

Tepotinib (Tepmetko) - To treat non-small cell lung cancer Drug Approval Package: TEPMETKO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TEPMETKO Company: EMD Serono, Inc. Application Number: 214096 Approval Date: 02/03/2021 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

19. Lenalidomide - for the treatment of certain cancers and serious conditions affecting blood cells and bone marrow, namely multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma.

Lenalidomide - for the treatment of certain cancers and serious conditions affecting blood cells and bone marrow, namely multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma. Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European (...) Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/17706/2021 EMEA/H/C/005348 Lenalidomide Krka d.d. Novo mesto (lenalidomide) An overview of Lenalidomide Krka d.d. Novo mesto and why it is authorised in the EU What is Lenalidomide Krka d.d. Novo mesto and what is it used for? Lenalidomide Krka d.d. Novo mesto is a medicine used for the treatment of certain cancers and serious conditions affecting blood cells and bone marrow, namely multiple myeloma

2021 European Medicines Agency - EPARs

20. Tucatinib (Tukysa) - breast cancer

Tucatinib (Tukysa) - breast cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/50289/2021 EMEA/H/C/005263 Tukysa (tucatinib) An overview of Tukysa and why it is authorised (...) in the EU What is Tukysa and what is it used for? Tukysa is a cancer medicine that is used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body) and when it is HER2-positive. This means the cancer cells produce a protein on their surface, HER2, which stimulates the growth of the cancer. Tukysa is used with two other medicines, capecitabine and trastuzumab, and is used after at least 2 other treatments for HER2-positive cancer have already been tried

2021 European Medicines Agency - EPARs